A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
NCT04133636
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study will see how well a treatment called JNJ-68284528 works for getting rid of a type of sickness called minimal residual disease (MRD). The researchers want to know how many people who get the treatment don't have MRD anymore.
This study will see how well a treatment called JNJ-68284528 works for getting rid of a type of sickness called minimal residual disease (MRD). The researchers want to know how many people who get the treatment don't have MRD anymore.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
